However, as the mDCs isolated from untreated MS patients and healthy donors exhibited a similar induction of IDO1 in response to IL-27 but differed significantly in their ability to inhibit T cell proliferation, it is likely that the production of IDO1 alone is not responsible for the ability of mDCs to exert tolerogenic activity. Here, IDO1 is linked to myeloid sarcoma.